Summary
AstraZeneca made a deal with the U.S. government to lower drug prices for Medicaid and sell some drugs at a discount directly to people through a new website called TrumpRx. This agreement includes using the lowest drug prices from other developed countries as a benchmark and AstraZeneca investing more in the U.S. in return for temporary tariff exemptions.
Key Facts
- AstraZeneca reached an agreement with the U.S. government to reduce drug prices for Medicaid.
- The deal includes offering some drugs at up to 80% off through TrumpRx, a new government website.
- TrumpRx aims to let consumers buy drugs directly, bypassing traditional health insurance.
- AstraZeneca will also increase its manufacturing and research activities in the U.S.
- The company gets a three-year exemption from certain tariffs as part of the agreement.
- The Trump administration has a similar deal with Pfizer and plans for more pharmaceutical company discussions.
- AstraZeneca plans to invest an additional $500 million in a new Virginia manufacturing site.
